ProShare Advisors LLC increased its holdings in Aimmune Therapeutics, Inc. (NASDAQ:AIMT) by 12.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 28,950 shares of the biotechnology company’s stock after buying an additional 3,303 shares during the period. ProShare Advisors LLC owned 0.06% of Aimmune Therapeutics worth $595,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Wellington Management Group LLP raised its position in shares of Aimmune Therapeutics by 641.2% in the first quarter. Wellington Management Group LLP now owns 2,316,553 shares of the biotechnology company’s stock valued at $50,339,000 after buying an additional 2,004,023 shares in the last quarter. Eagle Asset Management Inc. raised its position in shares of Aimmune Therapeutics by 6.3% in the second quarter. Eagle Asset Management Inc. now owns 2,270,160 shares of the biotechnology company’s stock valued at $46,674,000 after buying an additional 135,374 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Aimmune Therapeutics by 30.5% in the first quarter. Vanguard Group Inc. now owns 2,199,858 shares of the biotechnology company’s stock valued at $47,803,000 after buying an additional 513,803 shares in the last quarter. Palo Alto Investors LLC raised its position in shares of Aimmune Therapeutics by 209.0% in the first quarter. Palo Alto Investors LLC now owns 1,173,498 shares of the biotechnology company’s stock valued at $25,500,000 after buying an additional 793,771 shares in the last quarter. Finally, State Street Corp raised its position in shares of Aimmune Therapeutics by 49.1% in the first quarter. State Street Corp now owns 858,891 shares of the biotechnology company’s stock valued at $18,663,000 after buying an additional 282,744 shares in the last quarter. Institutional investors own 72.90% of the company’s stock.

A number of equities research analysts have recently weighed in on AIMT shares. Piper Jaffray Companies set a $38.00 price target on shares of Aimmune Therapeutics and gave the company a “buy” rating in a research report on Thursday, July 27th. Zacks Investment Research downgraded shares of Aimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, July 11th. ValuEngine upgraded shares of Aimmune Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, June 13th. Wedbush reiterated an “ourperform” rating and issued a $42.00 price target on shares of Aimmune Therapeutics in a research report on Monday, August 14th. Finally, BidaskClub downgraded shares of Aimmune Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, August 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the stock. The stock presently has an average rating of “Hold” and an average price target of $40.00.

In other Aimmune Therapeutics news, CEO Stephen George Dilly sold 100,000 shares of the stock in a transaction that occurred on Monday, September 25th. The shares were sold at an average price of $25.01, for a total value of $2,501,000.00. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Mary M. Rozenman sold 14,940 shares of the stock in a transaction that occurred on Monday, July 17th. The stock was sold at an average price of $21.44, for a total transaction of $320,313.60. Following the completion of the sale, the insider now owns 9,103 shares in the company, valued at $195,168.32. The disclosure for this sale can be found here. Insiders sold a total of 247,400 shares of company stock worth $5,780,897 over the last quarter. Corporate insiders own 24.56% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another website, it was illegally stolen and republished in violation of United States and international copyright & trademark law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/10/05/proshare-advisors-llc-has-595000-stake-in-aimmune-therapeutics-inc-aimt.html.

Aimmune Therapeutics, Inc. (AIMT) opened at 26.23 on Thursday. The company has a 50-day moving average of $24.18 and a 200-day moving average of $24.18. Aimmune Therapeutics, Inc. has a 52 week low of $14.87 and a 52 week high of $27.31. The company’s market capitalization is $1.33 billion.

Aimmune Therapeutics (NASDAQ:AIMT) last posted its earnings results on Tuesday, August 8th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). On average, equities research analysts anticipate that Aimmune Therapeutics, Inc. will post ($2.71) EPS for the current year.

Aimmune Therapeutics Company Profile

Aimmune Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a therapeutic approach, including the development of product candidates, for the treatment of peanut and other food allergies. The Company’s therapeutic approach, which it refers to as Characterized Oral Desensitization Immunotherapy (CODIT), is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.

Institutional Ownership by Quarter for Aimmune Therapeutics (NASDAQ:AIMT)

Receive News & Stock Ratings for Aimmune Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aimmune Therapeutics Inc. and related stocks with our FREE daily email newsletter.